This study seeks to determine whether daily administration of oral insulin, from the age of 4–7 months until the age of 36 months to children with elevated genetic risk for T1D, reduces the incidence of beta cell autoantibodies and diabetes (51). Here, INS is linked to diabetes mellitus.